Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...

Broadway performers will sing show tunes at a fundraising event aimed at boosting awareness of pulmonary fibrosis.

The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

With idiopathic pulmonary fibrosis, columnist Sam Kirton continues to learn to be prepared for emergencies, such as the Los Angeles fires.

Each new year brings an influx of marketing about resolutions, hopes, and wishes. If you’re like me, your social media feed is flooded with related ad campaigns this month. A new year often sparks ...

Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study ...